Plasmapp, a bio-plasma deep tech company, participated in the world's largest dental exhibition (IDS 2023) held in Cologne, Germany for four days from March 14th to March 18th and began to increase its presence in the global market.

The International Dental Show (IDS) started in 1923 under the auspices of the German Dental Equipment Industry Promotion Agency (GFDI) and is an exhibition with a long tradition that celebrates its 100th anniversary this year. It is the world's largest representative exhibition in the dental field.

IDS 2023, the first event held since the pandemic and celebrating its 100th anniversary, will be held on the largest scale ever, with more than 2,000 global companies participating and an estimated 100,000 visitors, the organizers said.

At this exhibition, Plasmapp introduced its own low-temperature sterilization plasma sterilization solution (brand: STERLINK) and implant regeneration activation solution (brand: ACTILINK) developed independently by Plasmapp, and received plasma care solutions from various medical device manufacturers, dealers, and hospitals in the market. showed high interest in.

In the case of Plasmapp's 'STERLINK' Line up, which is the only non-US company to have FDA approval among low-temperature plasma sterilizers, it introduced the 'STERLINK lite' product, which is scheduled to be released recently, to the market along with existing products.

From the customer's TCO (Total Cost Ownership) perspective, 'STERLINK lite' is more than 30% more effective than existing plasma sterilizers, and signed a collaboration agreement with the world's best premium autoclave (high-pressure steam sterilizer) and medical device manufacturer to enter the global dental market. It aroused a positive response in the market.

In addition, in the case of 'ACTILINK', which has recently secured access to the Chinese market through CVC certification, it has entered into a full-scale clinical trial agreement with leading Chinese universities such as Peking University and Shanghai University along with a global top-tier dental material manufacturer. It showed a quick move to expand the market.

In particular, regarding the possibilities and entry strategy of the Chinese market, Plasmapp CEO Youbong Lim said, “Through this contract, we were able to secure systematic clinical data and a network to secure mid- to long-term growth momentum in the Chinese market.

“We are in the process of considering appropriate partners among various partners to enter the Chinese market, and we have established a priority bridgehead through research collaboration,” he commented.

In addition, more than 15 new customers, including those in Europe and the Middle East, were secured through IDS, and the company achieved the feat of winning new orders worth KRW 3 billion during the exhibition alone.

By establishing a mid- to long-term cooperation system with implant manufacturers in Israel, Germany, and Italy and dental material manufacturers in Japan, Plasmapp evaluated that it has laid the foundation for mid- to long-term growth by raising awareness of plasma technology within the dental industry.

Plasmapp CEO Youbong Lim said, “By participating in ‘IDS 2023,’ which celebrated its 100th anniversary this year, we were able to solidify our position as a global dental company and lay the foundation for expanding our global network, so we successfully completed the exhibition.”

“In particular, in the field of sterilization, which is of high interest in the global market after the pandemic, Plasmapp will expand the market with a differentiation strategy through overwhelming technological capabilities and will make every effort to become the future of the global dental industry,” he said.

Source: Bokuennews ( http://www.bokuennews.com/news/article.html?no=227145 )